News Search Results
Jun 30, 2026, 09:18 ET Scenic Shore Bike Tour Returns to Lake Michigan Drawing Cyclists of All Abilities
WASHINGTON, June 30, 2026 /PRNewswire/ -- Blood Cancer United, formerly The Leukemia & Lymphoma Society, will bring together more than a thousand cyclists in Mequon, Wisconsin, from July 25–26 for the 34th Annual
More news about: BLOOD CANCER UNITED, INC.
Jun 30, 2026, 07:15 ET ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily
More news about: ADC Therapeutics SA
Jun 29, 2026, 16:52 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell lymphoma (LBCL), including patients with diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), high-grade B-Cell lymphoma (HGBL) with MYC and B-cell/lymphoma 2 (BCL2) and/or BCL6 rearrangements, follicular lymphoma grade 3B (FL3B), T-cell/histiocyte-rich large B-Cell lymphoma (TCHR
More news about: AbbVie
Jun 29, 2026, 16:15 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell lymphoma (LBCL), including patients with diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), high-grade B-Cell lymphoma (HGBL) with MYC and B-cell/lymphoma 2 (BCL2) and/or BCL6 rearrangements, follicular lymphoma grade 3B (FL3B), T-cell/histiocyte-rich large B-Cell lymphoma (TCHR
More news about: AbbVie
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.MalignancyLymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of
More news about: AbbVie
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.MalignancyLymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.MalignancyLymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active-controlled study of
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.MalignancyLymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active-controlled study of
More news about: AbbVie
Jun 26, 2026, 10:10 ET Anivive Lifesciences Announces FDA Approval of Laverdia®, the First Oral Treatment of Its Kind for Canine Lymphoma
full approval for Laverdia® (verdinexor tablets), marking a major advancement in the treatment of canine lymphoma. Laverdia is the first FDA-approved oral, at-home treatment for lymphoma in dogs designed to give veterinarians and pet owners a safe, effective, and more accessible option for managing
More news about: Anivive Lifesciences Inc.
Jun 26, 2026, 09:42 ET Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of
More news about: Curis, Inc.
Jun 26, 2026, 07:16 ET Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is
More news about: Eli Lilly and Company
Jun 25, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although ADC's treatment extended progression-free survival by 1.4 months, 27 deaths were recorded for those given Zynlonta, compared
More news about: Pomerantz LLP
Jun 25, 2026, 05:44 ET CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
including stage III and IV non-small cell lung cancer (NSCLC), gastric cancer (GC), esophageal squamous cell carcinoma (ESCC), and extranodal NK/T-cell lymphoma (ENKTL), subject to regulatory approval by Australia's Therapeutic Goods Administration (TGA). Arrotex will be responsible for regulatory submissions
More news about: CStone Pharmaceuticals
Jun 24, 2026, 07:30 ET ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily
More news about: ADC Therapeutics SA
Jun 24, 2026, 07:00 ET Blood Cancer United and BeOne Medicines Announce Expanded Partnership to Advance Patient Support and Community for People Impacted by Blood Cancer
Expert-led educational webcasts and resources for people living with blood cancers such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and non-Hodgkin lymphoma (NHL)The Clinical Trial Support Center (CTSC), which offers personalized guidance to help patients explore and access clinical
More news about: BLOOD CANCER UNITED, INC.
Jun 23, 2026, 20:00 ET Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
models.As a key technological approach for directly mobilizing T cells to kill tumors, TCE has shown significant clinical value in various lymphoma indications, with multiple products successfully launched. However, current treatments for AML and CMML primarily remain primarily limited to chemotherapy,
More news about: Mabwell
Jun 23, 2026, 10:00 ET HealthWell Foundation Achieves Milestone of Assisting Over Half a Million People Living with Cancer
Mantle Cell Lymphoma, and
More news about: HealthWell Foundation
Jun 23, 2026, 08:30 ET Nationwide Student Philanthropic Campaign Advances Blood Cancer Research and Care
here.About Blood Cancer United®Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Since their founding in 1949, the organization
More news about: Blood Cancer United
Jun 22, 2026, 10:31 ET Hematopoietic Stem Cell Transplantation Market Landscape to Evolve at a CAGR of 12.4% During the Forecast Period (2026-2036) as Novel Therapies and Expanding Patient Eligibility Drive Growth | DelveInsight
Cell Transplantation Market Increasing Prevalence of Hematologic Disorders: The rising incidence of leukemia, lymphoma, multiple myeloma, aplastic anemia, and inherited blood disorders is driving demand for HSCT as a potentially curative treatment option.Expansion
More news about: DelveInsight Business Research, LLP
Jun 22, 2026, 09:07 ET The Knicks and Mitchell Modell: New York Celebrates Two Comeback Stories
mission behind the launch is deeply personal. His father died from prostate cancer in 2008. His brother battled both testicular cancer and non-Hodgkin lymphoma. Modell himself survived stage IIIC melanoma after being given only a 20 percent chance of surviving five years."Cancer has impacted every member
More news about: Mitchell Modell
Jun 22, 2026, 01:45 ET Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
locally advanced or metastatic NSCLC who have programmed death ligand 1 (PD-L1) tumor proportion score (TPS)≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech
More news about: Kelun-Biotech
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although ADC's treatment extended progression-free survival by 1.4 months, 27 deaths were recorded for those given Zynlonta, compared
More news about: Pomerantz LLP
Jun 17, 2026, 10:05 ET Belay Announces Update to NCCN Guidelines to Recommend CSF-based Genomic Profiling in Biopsy Infeasible High-Grade Gliomas
recommended. Previous iterations of the NCCN Guidelines recommended CSF molecular testing for cases of medulloblastoma, spinal and cranial ependymoma, CNS lymphoma, and leptomeningeal metastasis in adult patients.
More news about: Belay Diagnostics
Jun 17, 2026, 08:05 ET Lymphoma Research Foundation Awards 24 New Scientific Research Grants
patients and families affected by lymphoma."About the Lymphoma Research Foundation:The Foundation is the nation's largest nonprofit organization devoted exclusively to funding innovative lymphoma research and serving those who have had lymphoma and the health care providers, family
More news about: Lymphoma Research Foundation
Jun 17, 2026, 08:00 ET Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress
in patients with known hypersensitivity to tacrolimus or to any of the ingredients in ENVARSUS XR.WARNINGS AND PRECAUTIONSLymphoma and Other Malignancies: Immunosuppressants, including ENVARSUS XR, increase the risk of developing lymphomas and other malignancies, particularly
More news about: Veloxis Pharmaceuticals